Simply Wall St.
Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest shareholders are individual investors with 38% ownership, public companies own 30%
📊
AI Sentiment
Positive
6/10
- Home
- LUCD
as of 12-02-2025 4:00pm EST
$1.01
$0.00
0.00%
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Chart Type:
Time Range:
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 132.4M | IPO Year: | 2021 |
| Target Price: | $3.88 | AVG Volume (30 days): | 646.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $1.80 | Next Earning Date: | 11-12-2025 |
| Revenue: | $4,399,000 | Revenue Growth: | 5.01% |
| Revenue Growth (this year): | 13.3% | Revenue Growth (next year): | 155.58% |
AI-Powered LUCD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 67.35%
67.35%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Lucid Diagnostics Inc. News
LUCD Breaking Stock News: Dive into LUCD Ticker-Specific Updates for Smart Investing
Compare LUCD vs Leading Stocks
See how LUCD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LUCD Lucid Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.